Instrumental test on silicone support
It received an FDA warning letter in September 2025 for misleading compounded semaglutide marketing claims, launched a compounded semaglutide pill in February 2026 that was referred to the DOJ within days and pulled within 48 hours, was sued by Novo Nordisk for patent infringement, and then reached a deal with Novo Nordisk in March 2026 to offer branded Ozempic directly through the platform
The most common digestive symptoms include: Nausea (very common, affecting more than 1 in 10 people) Diarrhoea (very common, affecting more than 1 in 10 people) Decreased appetite (very common, a desired therapeutic effect but can be uncomfortable) Vomiting (common, affecting up to 1 in 10 people) Constipation (common, affecting up to 1 in 10 people) Abdominal pain or discomfort (common) Dyspepsia (indigestion) Flatulence and bloating Regarding stool colour changes , including green stools, there is no official direct link established in the clinical trial data or product literature for Mounjaro
Nausea is a common early side effect of GLP-1 therapy and usually resolves within the first few weeks
Firstly, it helps lighten age spots and even out the tone of the face